Prelude Therapeutics IncorporatedPRLDNASDAQ

Revenue (LTM)

$12M

+73.4% YoY

Net Income (LTM)

$-99M

+21.8% YoY

Free Cash Flow

$-56M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	7	12↑73.4%
Gross Profit	0	0	0	7	10↑49.0%
Operating Income	-114	-124↓8.6%	-132↓7.1%	-140↓5.6%	-105↑25.2%
Net Income	-112	-115↓3.4%	-122↓5.5%	-127↓4.4%	-99↑21.8%
EBITDA	-113	-122↓8.3%	-131↓7.3%	-138↓5.2%	-103↑25.4%
EPS Diluted	-2.33	-2.27↑2.6%	-2.02↑11.0%	-1.68↑16.8%	-1.29↑23.2%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	32	31↓3.8%	25↓17.4%	12↓50.7%	35↑182.6%
Total Current Assets	295	204↓30.7%	236↑15.3%	136↓42.3%	106↓22.2%
Total Assets	305	221↓27.7%	278↑25.9%	176↓36.8%	141↓19.5%
Total Current Liabilities	19	22↑13.0%	22↑0.6%	26↑17.5%	53↑106.7%
Total Liabilities	19	25↑30.5%	41↑61.9%	44↑8.6%	73↑65.0%
Total Equity	286	195↓31.6%	237↑21.3%	131↓44.6%	69↓47.8%
Total Debt	2	2↑5.3%	17↑821.8%	18↑6.7%	18↓1.3%
Net Debt	-30	-29↑4.4%	-8↑70.8%	6↑166.1%	-17↓414.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-84	-84↓0.2%	-107↓27.9%	-103↑3.9%	-56↑45.3%
Capital Expenditure	-2	-3↓30.0%	-4↓16.4%	-1↑78.3%	-0↑91.2%
Free Cash Flow	-86	-87↓1.0%	-111↓27.5%	-104↑6.3%	-56↑45.6%
Stock-Based Comp	21	25↑20.1%	26↑1.9%	21↓16.7%	12↓44.2%
Net Change in Cash	-182	-1↑99.3%	-5↓334.5%	-13↓141.2%	22↑271.4%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance